Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CGEM
CGEM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CGEM News
Analysis of Cullinan Therapeutics Options Trading
3d ago
NASDAQ.COM
Cullinan Therapeutics Flags 2026 as Key Year for Clinical Data
Mar 14 2026
Yahoo Finance
Cullinan Therapeutics Reports Wider Q4 Net Loss and R&D Expenses
Mar 11 2026
NASDAQ.COM
Cullinan Therapeutics Q4 Earnings Miss Expectations
Mar 10 2026
seekingalpha
Growth Prospects for the EGFR-NSCLC Market Analyzed
Feb 11 2026
Newsfilter
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients
Dec 08 2025
Globenewswire
Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients
Dec 08 2025
Newsfilter
Cullinan Secures FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML
Dec 01 2025
NASDAQ.COM
Cullinan Receives FDA Fast Track Designation for CLN-049 in AML Treatment
Dec 01 2025
Newsfilter
Cullinan Therapeutics Receives Fast Track Designation for CLN-049
Dec 01 2025
NASDAQ.COM
Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday
Nov 24 2025
Benzinga
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 24 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Cullinan Therapeutics, Increases Price Target to $26
Nov 20 2025
Benzinga
Seven Tech Stocks Experience Significant Insider Selling Despite Price Increases
Oct 28 2025
MarketWatch
Taiho Oncology and Cullinan Therapeutics Showcase Zipalertinib Data for NSCLC Patients with EGFR Mutations and Active Brain Metastases at ESMO Congress 2025
Oct 12 2025
Newsfilter
Show More News
